MedTrace Logo

A Phase 2 Study of HW091077 in Participants With Refractory Chronic Cough Or Unexplained Chronic Cough (RCC/UCC).

NCT07483489 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2026-03-19

No results posted yet for this study

Summary

This is a randomized, multicenter, double-blind, placebo-controlled, parallel-designed phase 2 clinical trial to evaluate the efficacy, safety and pharmacokinetic (PK) characteristics of HW091077 in Chinese adult subjects with refractory chronic cough or unexplained chronic cough (RCC/UCC).

Conditions

  • Refractory Chronic Cough

Interventions

DRUG

HW091077

HW091077 oral tablet, oral, QD

DRUG

HW091077

HW091077 oral tablet, oral, QD

DRUG

Matching placebo to HW091077

Matching placebo to HW091077 oral tablet, oral, QD

Sponsors & Collaborators

  • Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-01
Primary Completion
2028-08-30
Completion
2028-08-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07483489 on ClinicalTrials.gov